Phase 2 N=40 Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Incidence of Treatment-emergent Adverse Events (AEs) by Severity — 5; 6; 4; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,532 Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set — -7.65…
Phase 2 N=245 Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants
N/A N=494 Postoperative Headache in Elective Surgery Patients
Drug Withdrawal Headache
Primary: Frequency of Postoperative Headache in Elective Surgery Patients — 126; 37; 89 participants
Phase 2 N=20 Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
Phase 2 N=245 Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants
Phase 2 N=18 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants
Phase 2 N=32 Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Incidence of Treatment-emergent Adverse Events (AEs) by Severity — 4; 7; 7; 5 Participants
N/A N=161 Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)
Type 1 Diabetes
Primary: Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports — 35; 29; 10 participants
N/A N=43 Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Hypercholesterolemia · HIV Infections
Primary: The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both…
Phase 2 N=26 Nitrites, Exercise, and Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption) — 1.48; 0.23 ml/kg/min
N/A N=20 Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern
Diet-induced Thermogenesis
Primary: Intra-individual Variation in Morning Diet-induced Thermogenesis (DIT) Evaluated by Calorimetric Exam After the Consumption of a Meal at 8:00 am Compared With Evening…
N/A N=6 Early-Phase Safety of Proton Therapy Equipment
Malignant Glioma · Hepatocellular Carcinoma · Head and Neck Malignant Tumor
Primary: Rate and Severity of Adverse Reactions — 6 participants
N/A N=26 A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
Pancreatic Cysts
Primary: Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration — 0; 0 participants
N/A N=41 Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: International Prostate Symptom Score (IPSS) — 9.83; 13.6; -3.39; -5.94 units on a scale